Axxcess Wealth Management LLC Takes Position in Abivax SA Sponsored ADR $ABVX

Axxcess Wealth Management LLC acquired a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,349 shares of the company’s stock, valued at approximately $369,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. First Horizon Corp bought a new position in Abivax during the third quarter worth about $36,000. Hantz Financial Services Inc. acquired a new position in shares of Abivax in the 3rd quarter worth approximately $52,000. Covestor Ltd bought a new position in shares of Abivax during the 3rd quarter worth approximately $96,000. Moody Aldrich Partners LLC acquired a new stake in Abivax in the 3rd quarter valued at $207,000. Finally, Ashton Thomas Securities LLC bought a new stake in Abivax in the third quarter valued at $212,000. Institutional investors own 47.91% of the company’s stock.

Abivax Stock Performance

Shares of NASDAQ:ABVX opened at $130.35 on Monday. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. Abivax SA Sponsored ADR has a 1-year low of $4.77 and a 1-year high of $148.83. The stock has a market capitalization of $10.31 billion, a P/E ratio of -31.18 and a beta of 0.81. The business has a 50-day moving average price of $123.15 and a two-hundred day moving average price of $104.40.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The firm had revenue of ($4.92) million for the quarter. Equities analysts predict that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Citigroup reissued a “market outperform” rating on shares of Abivax in a report on Thursday, January 8th. Morgan Stanley increased their target price on shares of Abivax from $101.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, January 9th. Guggenheim reaffirmed a “buy” rating and set a $175.00 price objective on shares of Abivax in a research note on Thursday, December 18th. Wolfe Research upgraded shares of Abivax to a “strong-buy” rating in a research note on Thursday, November 6th. Finally, BTIG Research boosted their target price on Abivax from $120.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $137.00.

Abivax Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.